Intranasal Oxytocin and Enhancement of Team Cohesion

• Status: Completed
• Trial end date: 2019-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: San Francisco Veterans Affairs Medical Center; United States Department of Defense
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Age 18-28

• Speak English

• Ability to use a nasal spray

Exclusion Criteria:

• Positive urine pregnancy test

• History of psychiatric or neurologic disorder

• Use of illicit drugs in the past month

• History of moderate-severe alcohol use disorder as defined by DSM-V criteria

• Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)

• Nasal obstruction, discharge, or bleeding

• Habitually drinks large volumes of water

• Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists

• Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions